Alvotech(US:ALVO) Globenewswire·2025-11-04 21:01Core Insights - Alvotech will release its financial results for the first nine months of 2025 on November 12, 2025, after U.S. markets close [1] - A conference call to discuss the financial results and provide a business update will take place on November 13, 2025, at 8:00 am EST [1] - The company has two approved biosimilars and a pipeline of nine candidates targeting various diseases [3] Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines globally [3] - The company aims to be a leader in the biosimilar market by offering high-quality, cost-effective products through an integrated approach [3] - Alvotech has established strategic partnerships with various commercial entities across multiple regions, including the U.S., Europe, and Asia [3] Product Pipeline - Alvotech has two marketed biosimilars: one for Humira® (adalimumab) and another for Stelara® (ustekinumab) [3] - The current development pipeline includes nine disclosed biosimilar candidates for treating autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech collaborates with numerous commercial partners, including Teva Pharmaceuticals, STADA Arzneimittel AG, and Fuji Pharma Co., Ltd., among others [3] - Each partnership is tailored to specific products and territories, enhancing Alvotech's global reach [3]